Press releases
These press releases are intended for journalists and analysts/investors.
-
Tafinlar® (dabrafenib mesilate) registered for the treatment of metastatic melanoma in Australia
Tafinlar® (dabrafenib) has been approved by the Therapeutics Goods Administration (TGA) in Australia for the treatment of patients
Read more -
Update to Rotarix prescribing information
GlaxoSmithKline Australia (GSK) has updated the prescribing information (PI) for Rotarix®, its rotavirus vaccine
Read more -
GSK to Trial Poppy Growing in Victoria
GlaxoSmithKline (GSK) Australia announced today that small scientific trials of poppies, used as a source of medicinal alkaloids
Read more -
Children’s Panadol® 1-5 Years Suspension temporarily out of stock
The makers of Children’s Panadol®, GSK, today confirmed that their Children’s Panadol® 1-5 years suspension range would be out of stock
Read more -
Update on dosing device in new Children’s Panadol 1-5 years suspension
GlaxoSmithKline (GSK) is disappointed with the decision made on Wednesday 17 July 2013 by the Federal Court to grant a temporary injunction
Read more -
GSK response to China investigation
In response to the ongoing investigations by government authorities in China regarding our business in the country
Read more -
Dosing device in new Children’s Panadol 1-5 years suspension
GlaxoSmithKline (GSK) is disappointed with the decision made on May 28 2013 by the Federal Court (Justice Rares)
Read more -
New GSK additions to the National Immunisation Program (NIP)
The addition of two new vaccines to the National Immunisation Program means that Australian children will now require two less injections
Read more -
Changes to GSK Manufacturing Site in Melbourne
GlaxoSmithKline (GSK) Australia is intending to close the tablet packaging part of the business at the Melbourne site in Boronia
Read more -
GSK Australia Reports 2012 Results to ASIC
GlaxoSmithKline (GSK) reported to the Australian Securities and Investment Commission (ASIC) for 2012 sales of $1,452m
Read more -
GSK and Save the Children form unique partnership to save the lives of one million children
An ambitious new partnership to save the lives of a million of the poorest children in the world has been launched by GSK
Read more -
GSK discloses 2012 payments to Australian healthcare professionals
As part GlaxoSmithKline’s (GSK) ongoing commitment to increase transparency, we are disclosing today, the aggregate amount of fees paid
Read more -
Fluarix® Product Notification
GlaxoSmithKline Australia (GSK) in consultation with the Therapeutic Goods Administration (TGA) has issued a product notification
Read more -
GSK’s response to the public roundtable report on Arachnoiditis
GlaxoSmithKline (GSK) has reviewed the final report of the House of Representatives Standing Committee on Health and Ageing
Read more -
Report on the Public roundtable into Adhesive Arachnoiditis
GlaxoSmithKline (GSK) welcomes the report on the roundtable into adhesive arachnoiditis provided by the Standing Committee
Read more -
GSK Australia divestment of Kapanol Complete
GSK Australia’s divestment of the pain relief product Kapanol (morphine sulphate) to Mayne Pharma Group Limited (Mayne Pharma)
Read more
-
About us
We are a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer.
-
Products
We make a wide range of prescription medicines, vaccines and consumer healthcare products.
-
Careers
GSK is a place where talented people do amazing things. Where you are encouraged to be you and create a meaningful impact.
-
Research and development
Science can improve health and well-being in so many ways, from the development of everyday convenience healthcare products.
